Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Theliatinib 是一种ATP 竞争性、口服活性和高度选择性的EGFR 抑制剂,Ki 为 0.05 nM,IC50为 3 nM。它具有抗肿瘤活性,对EGFR T790M/L858R 突变体的IC50值为 22 nM。它对EGFR 的选择性是其他激酶的 50 倍以上。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 543 | 现货 | ||
5 mg | ¥ 1,650 | 现货 | ||
10 mg | ¥ 2,680 | 现货 | ||
25 mg | ¥ 4,530 | 现货 | ||
50 mg | ¥ 6,480 | 现货 | ||
100 mg | ¥ 8,850 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,730 | 现货 |
产品描述 | Theliatinib, a potent and highly selective EGFR inhibitor, with anti-tumor activity. Ki of 0.05 nM for wild type EGFR, and IC50s of 3 and 22 nM for EGFR and EGFR T790M/L858R mutant, respectively. |
靶点活性 | EGFR:0.05 nM (Ki), EGFR:3 nM (IC50), EGFR (L858R/T790M):22 nM (IC50) |
体外活性 | In vitro studies suggest that Theliatinib is a potent EGFR kinase inhibitor with good kinase selectivity. |
体内活性 | In vivo data demonstrated broad spectrum anti-tumor activity via oral dosing in multiple xerographs such as A-431, Bcap-37 and Fadu. Two PDECX models with EGFR gene amplification (PDECX1T0326 and PDECX1T0950) were sensitive to theliatinib treatment demonstrating tumor regression of 32% and 75%, respectively. |
动物实验 | Seven- to nine week old NOD-SCID immunodeficient or BALB/cASlac-nu/nu male or female mice. Fresh tumor specimens from newly diagnosed patients were collected during surgery and separated into three parts for the following: (1) To prepare formalin fixed paraffin embedded (FFPE) sections; (2) For snap freezing in liquid nitrogen for DNA extraction and sequencing and (3) For subcutaneous implantation into NOD-SCID mice (P0) and subsequent passages in additional NOD-SCID or nude mice once the tumor size reached 800~1500 mm^3. After several consecutive in vivo passages, the PDECX models (P3~P7) were used to evaluate the anti-tumor efficacy of theliatinib or gefitinib or AZD4547. |
别名 | 席栗替尼, 西利替尼 |
分子量 | 442.51 |
分子式 | C25H26N6O2 |
CAS No. | 1353644-70-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 47 mg/mL (106.21 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.2598 mL | 11.2992 mL | 22.5984 mL | 56.4959 mL |
5 mM | 0.452 mL | 2.2598 mL | 4.5197 mL | 11.2992 mL | |
10 mM | 0.226 mL | 1.1299 mL | 2.2598 mL | 5.6496 mL | |
20 mM | 0.113 mL | 0.565 mL | 1.1299 mL | 2.8248 mL | |
50 mM | 0.0452 mL | 0.226 mL | 0.452 mL | 1.1299 mL | |
100 mM | 0.0226 mL | 0.113 mL | 0.226 mL | 0.565 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Theliatinib 1353644-70-8 Angiogenesis JAK/STAT signaling Tyrosine Kinase/Adaptors EGFR ATP-competitive inhibit ERK cancer esophageal Epidermal growth factor receptor HMPL-309 anti-tumor Inhibitor ErbB-1 HMPL309 HER1 HMPL 309 席栗替尼 orally Xiliertinib AKT 西利替尼 phosphorylation inhibitor